AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Etoricoxib is effective in providing relief from pain associated with conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, and other musculoskeletal disorders. It helps to reduce inflammation, swelling, and stiffness in affected joints, thereby improving mobility and function.
Anti-inflammatory Action: As an NSAID, etoricoxib exerts its therapeutic effects by inhibiting the enzyme cyclooxygenase-2 (COX-2), which is involved in the production of prostaglandins, mediators of inflammation. By blocking COX-2, etoricoxib reduces inflammation and associated symptoms.
Analgesic Properties: In addition to its anti-inflammatory effects, etoricoxib also possesses analgesic properties, providing relief from pain associated with various conditions. It can help alleviate mild to moderate pain, making it a valuable option for managing pain in different clinical settings.
Musculoskeletal Disorders: Etoricoxib is commonly prescribed for the management of musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It helps reduce pain and inflammation associated with these conditions, thereby improving overall quality of life for affected individuals.
Acute Gout: Etoricoxib is also used for the treatment of acute gouty arthritis, a form of arthritis characterized by sudden and severe joint pain, swelling, and inflammation. By reducing inflammation and pain, etoricoxib can help alleviate symptoms during gout flares.
Selective COX-2 Inhibition: Etoricoxib selectively inhibits COX-2 enzyme, which is responsible for inflammation and pain, while sparing COX-1 enzyme, which is involved in the maintenance of gastric mucosa and platelet aggregation. This selective inhibition may reduce the risk of gastrointestinal side effects associated with traditional NSAIDs.
Cardiovascular Risks: Like other NSAIDs, etoricoxib may be associated with an increased risk of cardiovascular events such as heart attack and stroke, especially with long-term use or in individuals with pre-existing cardiovascular disease. Therefore, it is essential to use etoricoxib cautiously, especially in patients with cardiovascular risk factors.
Gastrointestinal Side Effects: Although etoricoxib may have a lower risk of gastrointestinal side effects compared to traditional NSAIDs, it can still cause symptoms such as dyspepsia, gastritis, gastrointestinal ulcers, and bleeding. Patients at higher risk of gastrointestinal complications should be monitored closely while taking etoricoxib.
Renal Effects: NSAIDs, including etoricoxib, can cause renal adverse effects such as fluid retention, hypertension, and renal impairment, particularly in patients with pre-existing kidney disease or dehydration. Renal function should be monitored regularly in patients taking etoricoxib.
Allergic Reactions: Rarely, etoricoxib may cause allergic reactions such as skin rash, itching, swelling, and anaphylaxis. Patients experiencing signs of allergic reactions should seek medical attention promptly.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 1.8 | 1.8 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 1.7 | 0.8 | 1.13 |
| Allergies | 1.9 | 0.6 | 2.17 |
| Allergy to milk products | 0.5 | 1.3 | -1.6 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 3.1 | 3 | 0.03 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.2 | 4 |
| Ankylosing spondylitis | 1.6 | 0.7 | 1.29 |
| Anorexia Nervosa | 0.7 | 1.5 | -1.14 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.3 | 1 |
| Asthma | 2 | 1.1 | 0.82 |
| Atherosclerosis | 1.1 | 0.7 | 0.57 |
| Atrial fibrillation | 1.4 | 1.6 | -0.14 |
| Autism | 3.3 | 3.6 | -0.09 |
| Autoimmune Disease | 0.9 | 0.5 | 0.8 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.5 | 1.5 | |
| Bipolar Disorder | 1.6 | 0.5 | 2.2 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Breast Cancer | 0.8 | 0.8 | |
| Cancer (General) | 0.3 | 0.3 | |
| Carcinoma | 2.8 | 0.7 | 3 |
| Celiac Disease | 1.3 | 1 | 0.3 |
| Cerebral Palsy | 0.6 | 0.8 | -0.33 |
| Chronic Fatigue Syndrome | 1.6 | 2.1 | -0.31 |
| Chronic Kidney Disease | 1.5 | 0.9 | 0.67 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 1.1 | 0.09 |
| Chronic Urticaria (Hives) | 1 | 0.4 | 1.5 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 0.8 | 0.88 |
| Cognitive Function | 1 | 0.8 | 0.25 |
| Colorectal Cancer | 4.3 | 1 | 3.3 |
| Constipation | 0.9 | 0.5 | 0.8 |
| Coronary artery disease | 1.1 | 1.2 | -0.09 |
| COVID-19 | 2.9 | 1.7 | 0.71 |
| Crohn's Disease | 4.5 | 1.9 | 1.37 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | 0.8 | 0 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 1.7 | 1.1 | 0.55 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 4.5 | 2.9 | 0.55 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.3 | 0.7 | 0.86 |
| Endometriosis | 1.8 | 0.7 | 1.57 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2 | 1.3 | 0.54 |
| erectile dysfunction | 1.2 | 1.2 | |
| Fibromyalgia | 1.6 | 0.5 | 2.2 |
| Functional constipation / chronic idiopathic constipation | 2.3 | 1.7 | 0.35 |
| gallstone disease (gsd) | 1.7 | 0.8 | 1.13 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 0.3 | 3.33 |
| Generalized anxiety disorder | 1.7 | 0.6 | 1.83 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.6 | |
| Graves' disease | 0.7 | 1.1 | -0.57 |
| Gulf War Syndrome | 0.3 | 0.4 | -0.33 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 1.6 | 0.7 | 1.29 |
| Heart Failure | 2.5 | 0.5 | 4 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0.7 | 0.7 | |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 0.8 | 0.7 | 0.14 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2.3 | 1.8 | 0.28 |
| Hypoxia | 1.5 | 1.5 | |
| IgA nephropathy (IgAN) | 1.3 | 0.8 | 0.63 |
| Inflammatory Bowel Disease | 3.2 | 3 | 0.07 |
| Insomnia | 0.7 | 1.1 | -0.57 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 1 | 1 | |
| Irritable Bowel Syndrome | 3.1 | 1.8 | 0.72 |
| ischemic stroke | 1.2 | 1.4 | -0.17 |
| Liver Cirrhosis | 3.3 | 1.9 | 0.74 |
| Long COVID | 2.3 | 1.8 | 0.28 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.9 | 0.9 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 1.5 | |
| ME/CFS with IBS | 0.6 | 0.3 | 1 |
| ME/CFS without IBS | 0.4 | 0.6 | -0.5 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 4 | 2.7 | 0.48 |
| Mood Disorders | 4.3 | 2.7 | 0.59 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 2.3 | 2.2 | 0.05 |
| Multiple system atrophy (MSA) | 0.4 | 0.4 | |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 0.3 | 1.6 | -4.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.2 | 0.8 | 1.75 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 3.1 | 3 | 0.03 |
| obsessive-compulsive disorder | 2.3 | 0.8 | 1.87 |
| Osteoarthritis | 1.5 | 0.6 | 1.5 |
| Osteoporosis | 1.4 | 0.6 | 1.33 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 3.2 | 2.6 | 0.23 |
| Polycystic ovary syndrome | 3.8 | 1.4 | 1.71 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.8 | -1.67 |
| Primary sclerosing cholangitis | 1.7 | 0.8 | 1.13 |
| Psoriasis | 0.8 | 1.6 | -1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 1.5 | 1.07 |
| Rosacea | 0.1 | 0.5 | -4 |
| Schizophrenia | 1.8 | 1.3 | 0.38 |
| scoliosis | 0.2 | 0.3 | -0.5 |
| Sjögren syndrome | 1.3 | 0.9 | 0.44 |
| Sleep Apnea | 0.3 | 0.8 | -1.67 |
| Slow gastric motility / Gastroparesis | 0.5 | 0.5 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1 | 1 | |
| Stress / posttraumatic stress disorder | 1.7 | 1.3 | 0.31 |
| Systemic Lupus Erythematosus | 2.6 | 0.5 | 4.2 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.8 | 1.1 | 0.64 |
| Type 2 Diabetes | 3.7 | 2.6 | 0.42 |
| Ulcerative colitis | 2.7 | 2.1 | 0.29 |
| Unhealthy Ageing | 2.7 | 1 | 1.7 |
| Vitiligo | 1.4 | 0.4 | 2.5 |
